The present invention relates to improved processes for production of closed linear deoxyribonucleic acid (DNA), in particular cell-free enzymatic production of closed linear DNA molecules, preferably using a closed linear DNA as a template for DNA synthesis. The invention further relates to a novel closed linear DNA species, suitable for use as a template in the improved processes for production of closed linear DNA. Further, the invention pertains to the intermediate products of the processes, since this enables the production of larger quantities of closed linear DNA from the template than with methods known in the art.

The present invention relates to improved processes for production of closed linear deoxyribonucleic acid (DNA), in particular cell-free enzymatic production of closed linear DNA molecules, preferably using a closed linear DNA as a template for DNA synthesis. The invention further relates to a novel closed linear DNA species, suitable for use as a template in the improved processes for production of closed linear DNA. Further, the invention pertains to the intermediate products of the processes, since this enables the production of larger quantities of closed linear DNA from the template than with methods known in the art.

The present disclosure relates to methods for detecting unique genetic signatures derived from markers such as, for example, mutations, somatic or germ-line, in nucleic acids obtained from biological samples. The sensitivity of the methods provides for detection of mutations associated with a disease, e.g., cancer mutations, or with inherited disease, e.g., an autosomal recessive disease, in a noninvasive manner at ultra-low proportions of sequences carrying mutations to sequences carrying normal, e.g., non-cancer sequences, or a reference sequence, e.g., a human reference genome.

The present disclosure relates to methods for detecting unique genetic signatures derived from markers such as, for example, mutations, somatic or germ-line, in nucleic acids obtained from biological samples. The sensitivity of the methods provides for detection of mutations associated with a disease, e.g., cancer mutations, or with inherited disease, e.g., an autosomal recessive disease, in a noninvasive manner at ultra-low proportions of sequences carrying mutations to sequences carrying normal, e.g., non-cancer sequences, or a reference sequence, e.g., a human reference genome.

Provided is a new method for telomerase amplificationwashing-free anchored-extension and telomeric-binding amplification (WATA). The method comprises: utilizing an anchored telomerase primer to conduct telomere TTAGGGG sequence (G sequence) extension; hybridizing with a template probe having a universal PCR primer sequence and six units of telomere CCCTAA sequence (C sequence) on the extended G sequence; removing the uncombined template probe via an enzyme digestion reaction; and the template probe combined with the G sequence conducts PCR reaction, the amplification product being a peculiar DNA fragment of a fixed length.

Provided is a new method for telomerase amplificationwashing-free anchored-extension and telomeric-binding amplification (WATA). The method comprises: utilizing an anchored telomerase primer to conduct telomere TTAGGGG sequence (G sequence) extension; hybridizing with a template probe having a universal PCR primer sequence and six units of telomere CCCTAA sequence (C sequence) on the extended G sequence; removing the uncombined template probe via an enzyme digestion reaction; and the template probe combined with the G sequence conducts PCR reaction, the amplification product being a peculiar DNA fragment of a fixed length.

The present disclosure relates to a laboratory execution system that provides for automation of laboratory processes. A centralized data management system may be dynamically updated and used to facilitate management of components of the laboratory execution system, such as an automation system and an analytics results management system that may facilitate complex analytical functions, such as synthesizing raw test data. Potential workflows include the detection of specific molecules of interest.

The present disclosure relates to a laboratory execution system that provides for automation of laboratory processes. A centralized data management system may be dynamically updated and used to facilitate management of components of the laboratory execution system, such as an automation system and an analytics results management system that may facilitate complex analytical functions, such as synthesizing raw test data. Potential workflows include the detection of specific molecules of interest.

The present invention provides a method for determining whether or not an aqueous solution contains two or more cancer cells. The present method is characterized by the following three matters. First, the PCR solution contains the TS primer at a concentration of not less than 0.1 M and not more than 1 M in the present invention. Second, the PCR solution contains an ACX reverse primer. Third, the PCR solution contains the ACX reverse primer at a concentration of not less than 0.02 M and not more than 0.06 M in the present invention. In the present method, it is determined that an aqueous solution contains cancer cells even if the aqueous solution contains only two cancer cells.

The present invention provides a method for determining whether or not an aqueous solution contains two or more cancer cells. The present method is characterized by the following three matters. First, the PCR solution contains the TS primer at a concentration of not less than 0.1 M and not more than 1 M in the present invention. Second, the PCR solution contains an ACX reverse primer. Third, the PCR solution contains the ACX reverse primer at a concentration of not less than 0.02 M and not more than 0.06 M in the present invention. In the present method, it is determined that an aqueous solution contains cancer cells even if the aqueous solution contains only two cancer cells.